$1.400
-0.136 (-9.68%)At close
Price Predictions
Open in app to unlock longer-horizon forecasts.
PACB Prediction & Forecast by Similar Chart Analysis
Alphio's PACB stock price prediction model matches the current Pacific Biosciences of California Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $1.40 (+0.25%). The 1-week path is $1.27 (-9.00%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
Should I Buy Pacific Biosciences of California Inc Stock?
Pacific Biosciences (PACB) is currently not a strong buy due to its recent performance and outlook. The stock is priced at $1.40, which is below the analyst target of $1.50, indicating limited upside potential. Additionally, the company reported a significant year-to-date decline of 23.91% and has a negative forward P/E ratio of 0, reflecting uncertainty in future earnings. The recent resignation of the CEO and a downgraded revenue outlook for 2026 to $155-$165 million further complicate the investment case. The main risk lies in the company's high debt-to-equity ratio of 27223.46%, which poses a financial stability concern. Overall, while there are some positive indicators, such as a recent 5-day price increase of 3.70%, the overall sentiment and financial metrics suggest holding rather than buying at this time.
PACB stock price ended at $1.40 on Friday, after losing -9.68%
Pacific Biosciences of California Inc (PACB) last closed at $1.4, losing -9.68%. These facts feed the 1-day and 1-week PACB price prediction above.
Analyst Consensus
Pacific Biosciences of California Inc (PACB): 2 buy, 4 hold, 0 sell. Outlook: Hold.
Sell / Buy
Technical signals summary based on buy and sell indicators. The gauge shows the overall market view.
Forecast Drivers
Pacific Biosciences of California Inc (PACB) forecast drivers combine similar chart patterns, seasonality, and moving averages.
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bullish
SMA 200
Bearish
Similar Chart Patterns
Stocks whose recent price path most closely matches PACB, ranked by similarity.
Seasonality analysis for PACB
Historically the probability of a positive August return for PACB is 0.00%. January offers the highest probability of a positive month at 44.26%, while March is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
10-year price projections for PACB
| Month | Min Price | Avg Price | Max Price | Potential ROI |
|---|---|---|---|---|
| Aug 2026 | $0.64 | $0.84 | $1.00 | -39.71% |
| Sep 2026 | $0.53 | $0.80 | $0.83 | -42.68% |
| Oct 2026 | $0.86 | $0.93 | $1.07 | -33.37% |
| Nov 2026 | $0.83 | $0.98 | $0.99 | -30.11% |
| Dec 2026 | $0.96 | $0.99 | $1.08 | -29.24% |
In 2026, Pacific Biosciences of California Inc (PACB) is projected to range from $0.53 to $1.08.
Pacific Biosciences of California Inc 2026 monthly forecast
In Aug 2026, Pacific Biosciences of California Inc is projected to average $0.84, with a low of $0.64 and high of $1.00.
In Sep 2026, Pacific Biosciences of California Inc is projected to average $0.80, with a low of $0.53 and high of $0.83.
In Oct 2026, Pacific Biosciences of California Inc is projected to average $0.93, with a low of $0.86 and high of $1.07.
In Nov 2026, Pacific Biosciences of California Inc is projected to average $0.98, with a low of $0.83 and high of $0.99.
In Dec 2026, Pacific Biosciences of California Inc is projected to average $0.99, with a low of $0.96 and high of $1.08.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.